ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

DeVita Swearing In Schedule Aug. 8

August 1, 1980

Univ. of Rochester Leads Trial Of Combination Chemotherapy For Pancreatic Cancer

November 29, 2002

New Colorado Center Gets Core Grant

February 5, 1988

Women Are Less Active After A Diagnosis of Breast Cancer

March 28, 2003

ORI Whistle-Blower Proposal Too Rigid, Biologists Say.

February 2, 2001

8 Centers Awarded Comprehensive Designation

February 15, 1991